CD22 and diffuse large B-cell lymphoma: The most common grade 3–4 AEs were thrombocytopenia (31%) and neutropenia (22%).60 However, InO plus rituximab failed to obtain positive results in a randomized phase 3 trial (NCT01232556) of relapsed or refractory CD22+ aggressive B-NHLs and FLs.61 A phase 2 trial (NCT01679119) of InO plus rituximab, cyclophosphamide, vincristine, and prednisolone (R-CVP) in chemotherapy-naïve DLBCL not suitable for anthracycline-based treatment is ongoing.